US Patent 6,896,886: What the Claims Cover, What They Don’t, and How the Landscape Has Evolved
US Patent 6,896,886 centers on using botulinum toxin to denervate cholinergic autonomic neurons to control autonomic nerve function, with specific downstream application to excessive sweating via local administration to the skin.
What does US 6,896,886 claim, in plain technical terms?
Claim 1: core method scaffold
Claim 1 claims a method for controlling autonomic nerve function in a mammal that includes:
- Local administration to cholinergic neurons of the autonomic system
- A botulinum toxin amount sufficient to cause denervation of those neurons
- The denervation results in control of autonomic nerve function in a target tissue or organ
- The autonomic nerve function includes the function of an autonomic nerve that contributes to at least one symptom of excessive sweating
This claim is drafted as a neural mechanism method (denervation of cholinergic autonomic neurons) tied to a sweating symptom.
Claim 2:限定 to hyperhidrosis
Claim 2 narrows claim 1 to:
- Alleviating excessive sweating
- By administering a therapeutically effective amount of botulinum toxin to the skin of a human
Claim 3: administration route
Claim 3 limits claim 2 to:
Claim 4-6: toxin identity
- Claim 4: toxin is one of A, B, C, D, E, F, or G
- Claim 5: toxin is botulinum toxin A
- Claim 6: toxin is botulinum toxin D
How the claims are technically anchored
The claim set does two things at once:
- Mechanism anchor: denervation of cholinergic autonomic neurons
- Device/use anchor: intradermal botulinum toxin to treat excessive sweating (hyperhidrosis)
This combination matters because many prior art references treat hyperhidrosis with botulinum toxin but may not match the same neuron-level autonomic denervation framing.
How broad is claim 1, and what would typically infringe it?
Key breadth levers in claim 1
Claim 1 is broad on:
- Mammal (no species limitation)
- Local administration (no specific injection geometry required in the text of the independent claim)
- Tissue/organ (only requires a target that is innervated by the neurons)
- Symptom scope (only requires that the autonomic nerve contributes to at least one symptom of excessive sweating)
Claim 1 is narrower on:
- The neurons must be cholinergic neurons of the autonomic system
- The administered botulinum toxin must be sufficient to cause denervation of those neurons
- The target must connect to the sweating symptom via those neurons
Infringement logic under claim 1
A typical infringement theory for claim 1 would require showing that a practitioner’s method:
- Uses botulinum toxin for hyperhidrosis,
- Does so in a way that results in denervation of cholinergic autonomic neurons,
- And uses local administration tied to the affected tissue/organ innervated by those neurons.
In practice, the strongest match for claim 1 is conduct aligned with modern dermatology practice for primary axillary hyperhidrosis or palmar/plantar hyperhidrosis:
- Intradermal injection
- Botulinum toxin A commonly
- Treatment described as reducing sweating through denervation of sweat gland innervation
What claim 1 does not require
Claim 1 does not, as written:
- Require a specific sweat gland type (eccrine vs apocrine)
- Require a specific autonomic ganglion, nerve branch, or injection count
- Require any imaging or electrophysiology readout
- Limit to primary hyperhidrosis vs secondary hyperhidrosis
That means the claim can read broadly onto routine hyperhidrosis treatment methods, if the mechanism elements are met.
What is claim 2-6 really adding?
Claim 2: hyperhidrosis use and skin delivery
Claim 2 makes the method clinically specific by requiring:
- Therapeutically effective amount
- to the skin
- human
This is a narrowing step relative to claim 1. It can capture standard dermatologic administration patterns while excluding non-skin targets.
Claim 3: intradermal injection
This removes ambiguity around route. If an accused method uses botulinum toxin for hyperhidrosis but via:
- subcutaneous injection,
- intramuscular injection,
- topical formulation,
the literal “intradermal injection” limitation can become a non-match.
Claims 4-6: toxin subtype
- If a competitor uses botulinum toxin A, they map to claim 5
- If they use botulinum toxin D, they map to claim 6
- If they use other serotypes in the list, they map to claim 4
If a competitor uses a botulinum toxin not in that list (for example, if outside the A-G taxonomy as defined by the patent), these claims may not apply.
Where does US 6,896,886 sit in the hyperhidrosis botulinum toxin timeline?
US 6,896,886 is an early- to mid-generation US patent family in this space. The critical question for landscape analysis is whether the claims are mechanism-anchored enough to distinguish over prior art that already disclosed:
- injecting botulinum toxin into skin for excessive sweating, and/or
- using the concept that botulinum toxin blocks cholinergic signaling to sweat glands.
Even when prior art discloses clinical outcomes, enforcement depends on whether the prior art also teaches the claim elements:
- local administration to cholinergic autonomic neurons,
- a denervation result,
- and the link to autonomic nerve function controlling sweating symptoms.
What are the likely patentability vulnerabilities?
Obviousness pressure
Claim 1’s conceptual framework is:
- “Denervate cholinergic autonomic neurons with botulinum toxin to control autonomic function causing sweating.”
In many botulinum toxin developments, practitioners and inventors already understood and taught that botulinum toxins:
- block acetylcholine release at cholinergic nerve terminals, and
- reduce sweating by inhibiting cholinergic innervation of sweat glands.
If prior art taught botulinum toxin injection for hyperhidrosis using that physiological mechanism, claim 1 is vulnerable to obviousness or anticipation depending on how precisely the prior art matches the neuron-level and denervation language.
Anticipation risk from clinical disclosures
If a single prior art document:
- discloses intradermal botulinum toxin to treat hyperhidrosis, and
- explicitly ties mechanism to denervation of cholinergic autonomic neurons (not just “reduced secretion”),
then claim 1 and claim 2 can be vulnerable to anticipation.
If prior art is less explicit on the neuron denervation language, claim 1’s mechanism anchor could still survive anticipation but remain vulnerable on obviousness.
Intradermal route limitation (claim 3) as a tactical defense
Claim 3 can provide a defense barrier because many studies and protocols use intradermal or intradermal-adjacent injection. If an accused method uses a different route, literal infringement can fail.
However, if a competitor’s protocol effectively results in intradermal injection or is described as “intradermal” by practitioners, the limitation will not help.
Competitor design-around map: how others could avoid this claim set
This claim set is easiest to avoid by changing one required element.
Route and target
- Use a route other than intradermal (for claim 3)
- Deliver to a tissue not considered “skin” as required by claim 2
Mechanism framing
- Use delivery that avoids the described “denervation of cholinergic autonomic neurons” outcome.
In practice, this is hard because botulinum toxin’s biology tends to map to cholinergic terminal inhibition/denervation-like effects. Still, disputes can arise over whether denervation is demonstrated as opposed to transient functional blockade.
Serotype
- Use a botulinum toxin serotype outside A-G list
If a competitor uses only A, then claim 5 remains a direct target.
Practical enforcement: what a claimant would need to prove
Claim 1 evidence checklist
To enforce claim 1, a claimant typically aligns evidence to:
- Local administration (injection into affected area, not systemic administration)
- Cholinergic autonomic neurons as the target relevant to sweat gland innervation
- Denervation results from botulinum toxin dosing
- Connection to autonomic nerve function causing excessive sweating symptoms
Claim 2-3 evidence checklist
For claims 2 and 3, evidence aligns to:
- Treatment of excessive sweating (clinical indication)
- Skin administration in humans
- Intradermal injection protocol language or medical records
Claim 5-6 evidence checklist
- The accused botulinum toxin serotype is A (claim 5) or D (claim 6)
Patent landscape implications for investors and R&D planners
What the claims indicate about technological direction
The patent signals that this family is built for:
- dermatologic delivery to treat hyperhidrosis
- a mechanistic narrative that ties botulinum toxin action to cholinergic autonomic denervation
That is consistent with how botulinum toxin has been commercialized and prescribed for hyperhidrosis, which increases the importance of the legal strength of mechanism-anchored language.
Where infringement risk is highest
In practice, infringement risk tends to concentrate around:
- standard intradermal botulinum toxin injection for primary axillary hyperhidrosis
- protocols that specify intradermal administration and therapeutic intent to alleviate excessive sweating
Where risk drops
- Non-injection or topical approaches (not “intradermal injection”)
- Systemic regimens
- Non-skin targets (if claim 2 is asserted)
- Route changes that move outside “intradermal” classification
Key Takeaways
- Claim 1 is mechanism-anchored: it requires local botulinum toxin administration that denervates cholinergic autonomic neurons, producing control of autonomic nerve function tied to sweating symptoms.
- Claims 2-3 narrow to human excessive sweating treated by therapeutically effective botulinum toxin to skin, with intradermal injection as a route limiter.
- Claims 4-6 tie toxin identity to A (claim 5) or D (claim 6), expanding coverage across multiple serotypes in the A-G set.
- Enforcement hinges on whether the evidence supports the claim’s denervation and cholinergic autonomic neuron language, not just the clinical outcome.
- Landscape risk is highest for standard intradermal botulinum toxin hyperhidrosis treatment and for competitors using botulinum toxin A (claim 5) or botulinum toxin D (claim 6).
